A carregar...
Promise and challenges of anticoagulation with dabigatran
Dabigatran, marketed as Pradaxa (Boehringer Ingelheim) in the USA, is a direct thrombin inhibitor that holds great promise. It has been shown to reduce the risk of stroke and venous thromboembolism with similar if not greater efficacy than warfarin and with far fewer side effects. However, like othe...
Na minha lista:
| Publicado no: | Clin Kidney J |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4393474/ https://ncbi.nlm.nih.gov/pubmed/25874093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfs068 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|